Prescriptions for Food

News Highlights

A trend is spreading for prescriptions of food-like drugs to include the reason for prescription in the remarks section. This suggests that insurers and administrative bodies are requesting more detailed information from the perspectives of controlling drug costs and promoting appropriate use. This trend, reported by PHARMACY NEWSBREAK, underscores the importance of improving the operational efficiency and information management of medical institutions.

Perspective from M&A Medical Editorial Department

The move to include the reason for prescribing food-like drugs in the remarks column is not merely a change in administrative processing. It should be viewed as a demand for increased transparency in medical provision and, consequently, for more precise management data from medical institutions. In the context of M&A, this indicates that an era is dawning where the “accountability” of acquired medical institutions will be more strictly scrutinized. For example, even if a clinic was generating high revenue from prescribing food-like drugs, if the reason for this is unclear, it could become a risk factor in post-acquisition business planning. Conversely, medical institutions that can provide clear prescription justifications based on data are more likely to have their added value highly evaluated in the M&A market. This news highlights the importance for medical institutions to ensure their management data is in a state where it can be “explained.”.

Points Raised by This News

• The disclosure of reasons for prescribing food-like drugs is a precursor to strengthening the accountability of medical institutions’ management.
• Clarifying prescription data and its rationale will be a factor in enhancing the valuation of medical institutions in M&A.
• Improving operational efficiency and transparency will be important considerations in the business succession of medical institutions.
• Medical institutions should urgently prepare their management data to be in a state where it can be “explained.”

Practical Questions Arising from This News

• How should a system be established for detailed recording and management of reasons for prescribing food-like drugs?
• How will these records be evaluated in future M&A due diligence?
• What kind of future system changes are anticipated, such as mandatory disclosure of prescription reasons?

If You Feel “Should I Consult?”

Can your institution’s prescription data, along with the reasons for it, be clearly explained? The demand for appropriate medical fee optimization and accountability is increasing, not just for food-like drugs. When considering M&A, it is extremely important to objectively evaluate your institution’s management data and be in a position to confidently present it to potential buyers or sellers. If you have concerns about data management or explanations, it may be time to consider consulting with a specialist.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as a Small and Medium Enterprise Agency-certified M&A support institution, with a complete success fee system. Consultations are accepted with strict confidentiality. Free consultation here